GlassScriptPhysician profile
Paul V Gordon
NPI 1689659690
$5,547.12
in general payments reported to CMS, 2019-2025
29 companies · $23.21 in 2025
The $23.21 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,625 · 2022: $2,141 · 2023: $1,563 · 2024: $195 · 2025: $23.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,663.03 | 2021-2025 | |
| Gilead Sciences, INC. | $938.87 | 2021-2024 | Epclusa |
| Intercept Pharmaceuticals, INC. | $471.94 | 2021-2023 | Ocaliva |
| Digestive Care, INC. | $324.37 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $310.97 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.86 | 2021-2023 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $235.85 | 2021 | |
| Qol Medical, LLC | $182.43 | 2021-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $162.42 | 2021-2023 | Gattex |
| Medtronic, INC. | $144.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $140.34 | 2023 | Imfinzi |
| Ardelyx, INC. | $116.89 | 2022-2023 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $87.74 | 2022-2023 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $71.13 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $54.89 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.03 | 2023 | Avsola, Amjevita |
| Eisai INC. | $42.33 | 2023 | |
| Boston Scientific Corporation | $39.66 | 2022 | |
| Exelixis INC. | $33.30 | 2023 | Cabometyx |
| Alnylam Pharmaceuticals INC. | $32.57 | 2022-2023 | Givlaari |
| Ferring Pharmaceuticals INC. | $30.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.40 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $20.95 | 2021 | |
| Albireo Pharma, INC. | $19.50 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.20 | 2022 | |
| Evoke Pharma, INC. | $17.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.47 | 2022 | |
| Dynavax Technologies Corporation | $15.62 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.